Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Breaking News on USP Chapter 797

An updated draft of USP Chapter 797 was released today. Updated Chapter 797 Posted for Public Comment: Separate Requirements…

read more

Congress Makes Changes to MACRA

The second year of the Quality Payment Program (QPP) authorized by the Medicare Access and…

read more

CMS Extends the MIPS 2017 Data Submission Deadline from March 31 to April 3 at 8 PM EDT

If you’re an eligible clinician participating in the Quality Payment Program, you now have until Tuesday, April 3,…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

06/01/2018: Research Grant Cycle

12/01/2018: Research Grant Cycle
Learn more

06/15/18: Membership Application Deadline to be eligible for AAOA Member rate for the 2018 Basic Course

07/31/18: Membership Application Deadline to be voted in at the 2018 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2018 Annual Meeting
Learn more

04/01/2019: 2019 Fellow Exam Application Deadline
Learn more

EDUCATION

Why attend the 2018 AAOA Annual Meeting in Philadelphia from September 14-16? Learn some of the reasons to attend from the AAOA Leadership and staff. Register

Different Advanced Course

What is it in today’s otolaryngology practice that is resonating as a hot topic? Where are the novel treatment strategies? What is today’s typical otolaryngology practice or more specifically the typical AAOA member’s practice?  These are the questions we try to address when building out our Advanced Course in Allergy & Immunology. Read More

Codes/Guidelines

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

IFAR

Editor in Chief Search
The ARS-AAOA IFAR LLC is pleased to announce its search for Editor in Chief, term beginning April 2020. Read More

IFAR Impact Factor: 2.135

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2018 AAOA Annual Meeting
September 14-16 | Philadelphia, PA
Learn More and Register

2018 Advanced Course in Allergy & Immunology
December 6-8 | Atlanta, GA
Learn More and Register

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

Avoidance

The first most basic treatment step, once an allergen has been identified, is to eliminate or avoid contact with it, if possible. Unfortunately, avoiding some allergens (such as dust, molds, and animals) is often difficult and thus allergen avoidance alone may not be effective.

Read More

News and Updates

Social and Networking Events at the 2018 AAOA Annual Meeting

This year’s Annual Meeting assures to be not only educational, interactive, and practice-centered, but also…

read more

2018 AAOA Annual Meeting – Important Dates

August 14 - Hotel Discounted Rate Deadline Room Rate Room rate is $219 (plus 15.5% tax) single/double…

read more

Burnout: A Real Problem, Not Just a Trendy Talk Show Topic

When you really look at hot topics in medicine, physician burnout seems to really skyrocket…

read more
Menu

Practice Resources

Ingestion Challenge Testing

peanuts-2163043_640

Ingestion Challenge Testing Update 2013

Previously ingestion challenge testing for food, drugs or other substance was reported under Code 95075. That code has been deleted and effective January 1, 2013 is replaced by two new codes 95076 and 95079.

Code 95076 is defined as Ingestion challenge test (sequential and incremental ingestion of test items, e.g., food, drug or other substance); initial 120 minutes of testing.

Code 95079 is an add on code always reported with Code 95076 and is defined as each additional minutes of testing (list separately in addition to code for primary procedure.

As an example for the use of the new codes for drug allergy testing, consider a common protocol for penicillin allergy testing.  An initial single prick test is performed with each of the following: histamine, saline, benzylpenicilloyl polylysine (Pre-Pen), and penicillin G.

If these tests are “negative”, intradermal tests are then performed in the following manner: one intradermal application of a saline control, and two intradermal injections each for benzylpenicilloyl polylysine and penicillin G.

If the intradermal tests are “negative”, then on oral challenge with a penicillin product is given, and the patient is observed for one hour. The physician should bill for 9 units of 95018 (4 prick and 5 intradermal tests), and 1 unit of 95076 for the oral challenge test.

A Member Benefit

Allergy and Rhinology Journal (IFAR)

The International Forum of Allergy & Rhinology (IFAR) is the official journal of the AAOA and the American Rhinologic Society (ARS). Published monthly by John Wiley & Sons, Inc., IFAR provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions.

President Mims Message

April 2017

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices. Read More

News

New Articles from IFAR

Safety of long-term Intranasal Budesonide

The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP).. Read More

Medical therapy for Chronic Rhino-sinusitis

The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined..
Read More

New Blog Posts

Posts from AAOA Leaders

Allergies, not just for summer anymore. Read More

How to treat allergies at home.
Read More